07.05.2024 14:58:28
|
Why Precision BioSciences Is Rising In Pre-market?
(RTTNews) - Precision BioSciences, Inc. (DTIL) said its partner iECURE has received Fast Track designation from the FDA for ECUR-506. ECUR-506 is iECURE's in vivo gene insertion program designed to treat neonatal onset Ornithine Transcarbamylase deficiency utilizing a PCSK9-specific ARCUS nuclease, licensed from Precision, that enables insertion of a functional copy of the OTC gene.
ECUR-506 previously received Rare Pediatric Disease and Orphan Drug designations from the FDA, and Orphan designation from the European Commission for the treatment of OTC deficiency.
Shares of Precision BioSciences are up 8% at $11.60 in pre-market trade on Tuesday.
For More Such Health News, visit rttnews.com.
Der finanzen.at Ratgeber für Aktien!
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Precision BioSciences Inc Registered Shsmehr Nachrichten
Keine Nachrichten verfügbar. |